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International guidelines on schizophrenia and worldwide
experts in psychiatry recommend and insist on mono-
therapy with an antipsychotic medication for schizo-
phrenic patients. Studies about the clinical practice of
these guidelines show that all over the world most schi-
zophrenia patients receive two or more antipsychotics.
Further more combinations with antidepressants, mood
stabilizers or benzodiazepines is also common. Regard-
ing to local national differences polypharmacy rates are
increasing and achieve rates between 50 and 90% of
schizophrenic patients, exhibiting therefore a major
international trend towards polypharmacy. Although in
some cases combination therapy brings advantages, such
as “enhancing” or “speeding up” the antipsychotic effect,
there are still a lot of disadvantages in a polypharmacy
treatment regiment, such as interactions of the drugs
being involved, the greater risk of adverse reactions and
the lack of compliance to treatment regiment. Small,
randomised controlled studies with regard to antipsy-
chotic combination therapy exist. In summary they exhi-
bit a positive outcome for combinations of
antipsychotics with different receptor profile. Altogether
according to the study results combinations can be
divided in irrational (e.g. clozapine and quetiapine), and
rational ones, which provide a greater efficacy (e.g. clo-
zapine and amisulpirid). Augmentation with antidepres-
sant agents in case of persisting negative symptoms and
with mood stabilizers in patients with additional affec-
tive symptoms can be recommended. Further rando-
mised controlled studies are necessary to recommend
combination strategies on a higher level of evidence for
treatment resistant schizophrenia patients. In the speech
given, I would try to give you an overview and discuss
current data and trends in combining antipsychotic or
other psychotropic treatment in schizophrenia.
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